Curovir AB’s mission is to develop novel broad-spectrum antiviral treatments for enterovirus (EV) infections. Successful development could lead to the first registration of an antiviral drug for EV.

EV antiviral drugs have the potential to close a major medical treatment gap and improve the treatment of several important medical conditions, including e.g.:

• Exacerbations in COPD and asthma
• Hand, foot and mouth disease
• Poliomyelitis
• Serious EV infections in at risk populations
• The common cold
• Development and progression of type 1 diabetes

A broad-spectrum EV antiviral substance could also be kept as a rescue treatment for potential outbreaks of EV strains known to cause more serious diseases, e.g. poliovirus, EV-A71 and EV-D68 or serious but yet unidentified EV strains. During the development of our EV antiviral substances, we have shown that our selected candidate, CUR-N399, is also highly effective against respiratory syncytial virus (RSV). Like EV, RSV causes respiratory infections and contributes to the exacerbation of COPD and asthma, in addition to its more well-known effect of causing serious respiratory infections in small children and the elderly.